Cumberland Pharmaceuticals Inc.
CPIX
$4.76
$0.235.08%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 24.49% | -9.92% | -9.55% | -7.88% | -6.16% |
| Total Other Revenue | -34.76% | -- | -- | -- | 53.33% |
| Total Revenue | 11.57% | -9.92% | -9.55% | -7.88% | 2.51% |
| Cost of Revenue | 29.18% | -25.07% | 12.50% | 26.01% | -42.27% |
| Gross Profit | 8.13% | -6.70% | -13.13% | -13.19% | 20.85% |
| SG&A Expenses | -7.92% | -0.20% | -0.52% | -3.75% | 19.04% |
| Depreciation & Amortization | 22.09% | -8.25% | -5.03% | -9.71% | 160.87% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.73% | -9.81% | 0.09% | -3.62% | 6.90% |
| Operating Income | 35.04% | 9.23% | -4,583.41% | -22.04% | -24.48% |
| Income Before Tax | 68.80% | -44.42% | -225.56% | -1,155.25% | -160.28% |
| Income Tax Expenses | -328.00% | 65.22% | 65.22% | 65.22% | -48.13% |
| Earnings from Continuing Operations | 69.83% | -44.56% | -227.88% | -1,204.18% | -156.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -128.95% | -151.08% | 70.00% | -320.10% | -60.00% |
| Net Income | 69.75% | -47.16% | -224.47% | -1,112.64% | -157.89% |
| EBIT | 35.04% | 9.23% | -4,583.41% | -22.04% | -24.48% |
| EBITDA | 78.43% | 6.78% | -90.78% | -160.36% | 9.30% |
| EPS Basic | 69.33% | -49.52% | -226.90% | -1,130.60% | -162.18% |
| Normalized Basic EPS | 31.89% | -30.63% | -222.66% | -1,044.57% | -24.78% |
| EPS Diluted | 68.51% | -49.66% | -233.33% | -1,500.00% | -160.20% |
| Normalized Diluted EPS | 31.89% | -30.63% | -223.95% | -1,065.56% | -24.78% |
| Average Basic Shares Outstanding | -1.36% | -1.57% | -1.91% | -1.82% | -1.65% |
| Average Diluted Shares Outstanding | -1.36% | -1.57% | -3.00% | -3.36% | -1.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |